Pages that link to "Q34695283"
Jump to navigation
Jump to search
The following pages link to Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor (Q34695283):
Displaying 50 items.
- Onto better TRAILs for cancer treatment (Q26768160) (← links)
- Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions (Q27677202) (← links)
- The Janus Face of Death Receptor Signaling during Tumor Immunoediting (Q28070036) (← links)
- Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases (Q28307957) (← links)
- Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells (Q28391040) (← links)
- Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity (Q28729760) (← links)
- Achievements and Challenges in Computational Protein Design (Q30395939) (← links)
- Designing specific protein-protein interactions using computation, experimental library screening, or integrated methods (Q30416858) (← links)
- Genome-wide prediction of SH2 domain targets using structural information and the FoldX algorithm. (Q33326985) (← links)
- Synthetic constrained peptide selectively binds and antagonizes death receptor 5. (Q33531333) (← links)
- Optimization algorithms for functional deimmunization of therapeutic proteins (Q33551448) (← links)
- Capturing, sharing and analysing biophysical data from protein engineering and protein characterization studies (Q33665947) (← links)
- Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. (Q33723716) (← links)
- Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. (Q33805582) (← links)
- Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design (Q34015820) (← links)
- Evolution: a guide to perturb protein function and networks (Q34047786) (← links)
- TRAIL in cancer therapy: present and future challenges (Q34291312) (← links)
- Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma (Q34429203) (← links)
- Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. (Q34561798) (← links)
- Design of protein-interaction specificity gives selective bZIP-binding peptides. (Q34975999) (← links)
- Targeting AML through DR4 with a novel variant of rhTRAIL (Q35377418) (← links)
- Targeted ovarian cancer treatment: the TRAILs of resistance. (Q35609438) (← links)
- TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. (Q35681794) (← links)
- Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. (Q35863285) (← links)
- Stem cells are resistant to TRAIL receptor-mediated apoptosis. (Q35889082) (← links)
- DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer (Q36215003) (← links)
- The design and characterization of receptor-selective APRIL variants (Q36347872) (← links)
- RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL). (Q36412875) (← links)
- The TRAIL to targeted therapy of breast cancer (Q36511919) (← links)
- Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand (Q36777316) (← links)
- The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells (Q36992184) (← links)
- TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype (Q37040429) (← links)
- Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects (Q37073589) (← links)
- Therapeutic applications of TRAIL receptor agonists in cancer and beyond (Q37114025) (← links)
- The TRAIL apoptotic pathway in cancer onset, progression and therapy (Q37278043) (← links)
- TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. (Q37599015) (← links)
- Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy (Q37621564) (← links)
- Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family (Q38098380) (← links)
- Death receptors as targets in cancer (Q38103591) (← links)
- Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta (Q38816367) (← links)
- Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. (Q38866710) (← links)
- Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment (Q39054114) (← links)
- Real-time detection of cellular death receptor-4 activation by fluorescence resonance energy transfer (Q39226276) (← links)
- TRAIL-NP hybrids for cancer therapy: a review. (Q39263297) (← links)
- Novel transcript variants of TRAIL show different activities in activation of NF-κB and apoptosis (Q39467282) (← links)
- Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways (Q39778244) (← links)
- Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. (Q39875342) (← links)
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells (Q39978504) (← links)
- DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design (Q39982958) (← links)
- Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. (Q40038240) (← links)